Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 3

3(42.9%)

Phase 1

1(14.3%)

7Total

Phase 2(3)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00111657Phase 2Completed

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

Role: collaborator

NCT01739660Phase 1Completed

Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis

Role: lead

NCT00080210Phase 2Completed

A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy

Role: lead

NCT01356498Phase 3Completed

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

Role: lead

NCT00675103Phase 3Completed

Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients

Role: lead

NCT00325195Phase 3Completed

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

Role: lead

NCT00286377Phase 2Terminated

Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients

Role: lead

All 7 trials loaded